Biomarkers are measurable indicators of biological processes, disease states, or responses to treatment. Current research aims to identify reliable biomarkers that allow earlier diagnosis, more precise prognosis, and personalized therapy.

A major focus is on circulating biomarkers in blood and other body fluids. These include proteins, metabolites, nucleic acids such as cell free DNA and RNA, and extracellular vesicles. Because they can be sampled minimally invasively, they are central to liquid biopsy approaches. In cancer, specific mutations, epigenetic changes, and altered expression patterns in circulating DNA and RNA are being developed as tools for early detection, monitoring minimal residual disease, and tracking resistance to therapy.

Imaging biomarkers, derived from modalities such as MRI, CT, PET, and advanced image analysis, are another active area. Quantitative imaging features can reflect tumor heterogeneity, perfusion, metabolism, and microstructure, and can be correlated with molecular alterations. This supports non invasive characterization of disease and assessment of treatment response over time.

In neuroscience, biomarkers in cerebrospinal fluid and blood, including abnormal proteins linked to neurodegeneration, are being pursued to diagnose disorders like Alzheimer’s before significant symptoms arise. Similarly, cardiac biomarkers are central to rapid detection and risk stratification in cardiovascular disease.

Across fields, research stresses analytical validity, clinical validity, and clinical utility. Challenges include biological variability, standardization of assays, statistical pitfalls in discovery studies, and the need for rigorous validation in large, diverse cohorts. Increasingly, multi biomarker panels combined with machine learning are being explored to improve accuracy and to capture the complexity of human disease.